ICYMI, some of this week’s featured content includes an exclusive interview about eczema, and articles on a new tralokinumab data, apremilast as a combination treatment, and more.
A review of apremilast combination therapies was recently published in the Journal of Drugs in Dermatology, examining treatment efficacy and safety.
Proscia announces new study data on artificial intelligence’s ability to detect melanoma.
A Revolutionary Way to Revive Sensitive Skin
With the release of three brand-new products, ALASTIN Skincare® is introducing a new line of sensitive skin products that include our proprietary TriHex Technology® along with other active ingredients.
Potenza, Cynosure’s RF microneedling system, has been cleared by Health Canada.
In this episode of DermView, Adelaide Hebert, MD, explains how eczema can lead to growth issues in pediatric patients, how environmental factors may play a role in flare ups, and more.
On September 30, 2021, Galderma celebrated its 25th anniversary of its Restylane line of hyaluronic acid fillers.
The approval was supported by promising phase 3 data of the VOLTAIRE-X clinical trial.
O’Dell is the managing partner with OJM Group in Cincinnati, Ohio, a financial consultant, and the author of more than a dozen books on wealth management for doctors. Foos is a partner and lead tax consultant with OJM Group in Cincinnati, Ohio.
Investigators believe the new instrument could be generalized to other chronic inflammatory skin diseases in future studies.
In this week’s Pointers with Dr Portela, the 208SkinDoc explains what keratosis pilaris is and whether or not it can be cured.
This episode of The Cutaneous Connection podcast, Gary Linkov, MD, dives into the topic of hair loss.
Neal Bhatia, MD, gives a thumbs down on the phrase “steroid alternatives”.
How can GEP be applied to melanoma diagnosis and treatment? Darrel Rigel, MD, MS, answers these questions and dives into the data at Fall Clinical Dermatology Conference 2021.
Cantharidin 0.7% could be an emerging standard for molluscum treatment.
LEO Pharma releases the 16-week data regarding tralokinumab (Adtralza; LEO Pharma) as a treatment for adolescent patients aged 12 to 17 years.
Lawrence Eichenfield, MD, provides the newest updates in pediatric patient care, with a special update on COVID-19 skin symptoms in children.
In a video onsite at Fall Clinical Dermatology Conference, Darrell S. Rigel, MD, MS, highlights, in his own words, the potential of GEP as an adjunct to biopsy in melanoma detection.